Arrowhead Pharmaceuticals Inc. (ARWR)

18.54
NASDAQ : Health Technology
Prev Close 18.83
Day Low/High 18.27 / 19.00
52 Wk Low/High 6.26 / 22.39
Avg Volume 1.78M
Exchange NASDAQ
Shares Outstanding 94.21M
Market Cap 1.77B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Why Arrowhead Research (ARWR) Stock is Down Today

Why Arrowhead Research (ARWR) Stock is Down Today

Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering such therapies tied to the limited number of potential relevant targets led to the move. "We have decided to significantly reduce our internal drug discovery efforts in RNA therapeutics," Novartis told FierceBiotech in a statement. "This decision was driven by ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow. In the future we will have a small group working in this field and look for partnering opportunities." Arrowhead suffered in the wake of the news, as it is involved in RNAi drug development. The stock fell more than 4.3% to hit a low of $12.55 for the day as of 2:57 p.m. on Monday.

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Stock To Watch: Arrowhead Research Corporation (ARWR) In Perilous Reversal

Stock To Watch: Arrowhead Research Corporation (ARWR) In Perilous Reversal

Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Why Arrowhead Research (ARWR) Stock Is Up Today

Why Arrowhead Research (ARWR) Stock Is Up Today

Arrowhead Research (ARWR) is up 12% to $18.41 in trading Tuesday

Arrowhead Completes Enrollment Of First Cohort In Phase 2a Trial Of Chronic Hepatitis B Candidate ARC-520

Arrowhead Completes Enrollment Of First Cohort In Phase 2a Trial Of Chronic Hepatitis B Candidate ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a...

Interesting ARWR Put And Call Options For May 17th

Interesting ARWR Put And Call Options For May 17th

Investors in Arrowhead Research Corp saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Arrowhead Begins Dosing In Phase 2a Trial Of RNAi Therapeutic ARC-520 In Chronic Hepatitis B Patients

Arrowhead Begins Dosing In Phase 2a Trial Of RNAi Therapeutic ARC-520 In Chronic Hepatitis B Patients

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi...

Perilous Reversal Watch: Arrowhead Research Corporation (ARWR)

Perilous Reversal Watch: Arrowhead Research Corporation (ARWR)

Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "perilous reversal" (up big yesterday but down big today) candidate

Arrowhead To Present At Barclays Global Healthcare Conference

Arrowhead To Present At Barclays Global Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.

Why Arrowhead Research (ARWR) His a Five-Year High Today

Why Arrowhead Research (ARWR) His a Five-Year High Today

Arrowhead Research (ARWR) hit a five-year high of $27.21 on Wednesday after the FDA approved a phase 2a trial of its hepatitis B drug ARC-520, and several analysts consequently praised the company. Deutsche Bank initiated coverage on the stock with a "buy" rating and a target price of $45. The firm predicted the drug could peak at annual sales of $5.2 billion, and noted clinical trial data prior to that in 2014 and 2015 could elevate the stock further. RBC Capital Markets also initiated coverage at "outperform" with a target price of $35. The firm notes that the FDA approval could eventually lead to a multibillion-dollar product and more drugs derived from the same platform. Arrowhead has had quite the turnaround in the last year, as its one year low price is $1.65.

Today's Top Performers In Health Care

Today's Top Performers In Health Care

TheStreet highlights 3 stocks pushing the health care sector higher today.

Arrowhead Research Corporation (ARWR) Marked As A Dead Cat Bounce Stock

Arrowhead Research Corporation (ARWR) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Arrowhead Receives Regulatory Approval To Begin Phase 2a Trial Of Chronic Hepatitis B Candidate ARC-520

Arrowhead Receives Regulatory Approval To Begin Phase 2a Trial Of Chronic Hepatitis B Candidate ARC-520

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its...

Use Options For A Chance To Buy ARWR At A 55% Discount

Use Options For A Chance To Buy ARWR At A 55% Discount

Looking back to 5 days ago, Arrowhead Research Corp priced a 5,500,000 share secondary stock offering at $18.95 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Monday, the stock is now 19% above the offering price.

Arrowhead Closes Underwritten Offering With Gross Proceeds Of $120 Million

Arrowhead Closes Underwritten Offering With Gross Proceeds Of $120 Million

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on February 24, 2014 it closed the previously announced underwritten offering of...

Arrowhead Listing Upgraded To NASDAQ Global Select Market

Arrowhead Listing Upgraded To NASDAQ Global Select Market

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received notice that the NASDAQ Listing Qualifications Department has approved...

Arrowhead To Present At RBC Capital Markets' Global Healthcare Conference

Arrowhead To Present At RBC Capital Markets' Global Healthcare Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.

Arrowhead Announces Pricing Of Underwritten Offering Of Common Stock

Arrowhead Announces Pricing Of Underwritten Offering Of Common Stock

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock, offered...

Arrowhead Announces Proposed Underwritten Offering Of Common Stock

Arrowhead Announces Proposed Underwritten Offering Of Common Stock

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced its intention to offer and sell shares of its common stock in an underwritten offering...

Arrowhead Reports Fiscal 2014 First Quarter Financial Results

Arrowhead Reports Fiscal 2014 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted therapeutics, today announced financial results for its fiscal 2014 first quarter ended December 31, 2013.

Arrowhead To Participate In Panel Discussions At 16th Annual BIO CEO & Investor Conference

Arrowhead To Participate In Panel Discussions At 16th Annual BIO CEO & Investor Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that members of management will be panelists on two panel discussions at the 16 th...

Arrowhead To Report Fiscal 2014 First Quarter Financial Results

Arrowhead To Report Fiscal 2014 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 first quarter ended...

3 Stocks Rising on Big Volume

3 Stocks Rising on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far

It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far

Here are some random thoughts and observations from what I saw and heard this morning. Totally off the cuff stuff on Celgene, InterMune, Alnylam, NPS Pharma and Seattle Genetics.

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

Taken by Surprise

The conventional wisdom on Fed tapering proves wrong.

Arrowhead Reports Fiscal 2013 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2013 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2013 fourth quarter and year ended September 30, 2013.

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Arrowhead To Report Fiscal 2013 Fourth Quarter And Year-End Financial Results

Arrowhead To Report Fiscal 2013 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2013 fourth quarter and year...

Arrowhead Presents Phase 1 Data On ARC-520 At HepDART 2013

Arrowhead Presents Phase 1 Data On ARC-520 At HepDART 2013

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.

TheStreet Quant Rating: D (Sell)